Glycopyrronium Tosylate Patent Expiration

Glycopyrronium Tosylate is Used for reducing excessive sweating in the underarms in adults and children 9 years of age and older. It was first introduced by Journey Medical Corp in its drug Qbrexza on Jun 28, 2018.


Glycopyrronium Tosylate Patents

Given below is the list of patents protecting Glycopyrronium Tosylate, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Qbrexza US10004717 Glycopyrrolate salts Feb 28, 2033 Journey
Qbrexza US10052267 Topical glycopyrrolate formulations Oct 17, 2028 Journey
Qbrexza US10543192 Glycopyrrolate salts Feb 28, 2033 Journey
Qbrexza US10548875 Glycopyrrolate salts Feb 28, 2033 Journey
Qbrexza US6433003 Method for treating hyperhidrosis in mammals Apr 10, 2020

(Expired)

Journey
Qbrexza US8618160 Topical glycopyrrolate formulations Dec 10, 2029 Journey
Qbrexza US8859610 Crystalline glycopyrrolate tosylate Feb 28, 2033 Journey
Qbrexza US9006462 Glycopyrrolate salts Feb 28, 2033 Journey
Qbrexza US9259414 Glycopyrrolate salts Feb 28, 2033 Journey
Qbrexza US9744105 Topical glycopyrrolate formulations Jul 18, 2030 Journey


Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳